pd 153035 has been researched along with Ovarian Neoplasms in 5 studies
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "EGF plus EGFR inhibitor-primed ovarian cancer cells display increased sensitivity to taxol-induced cell death, resistant to EGF-induced cell migration and cell proliferation as well as ERK and PI3K/AKT activation." | 1.35 | Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. ( Amaral, A; Cao, C; Chu, W; Di, W; Kivlin, R; Lu, S; Sowa, A; Wan, Y; Yang, H, 2008) |
| "Using human ovarian cancer cell line Caov3 cells, we observed that TSA induced cell death in a time- and dose-dependent manner and also inhibited cell migration." | 1.33 | Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. ( Di, W; Healey, S; Kouttab, N; Qiu, L; Sun, Y; Wan, Y; Wanebo, H; Yan, B; Zhou, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grunt, TW | 2 |
| Puckmair, K | 2 |
| Tomek, K | 2 |
| Kainz, B | 2 |
| Gaiger, A | 2 |
| Zhou, C | 1 |
| Qiu, L | 1 |
| Sun, Y | 1 |
| Healey, S | 1 |
| Wanebo, H | 1 |
| Kouttab, N | 1 |
| Di, W | 2 |
| Yan, B | 1 |
| Wan, Y | 2 |
| Wagner, R | 1 |
| Rünzler, D | 1 |
| Köhler, G | 1 |
| Zielinski, CC | 1 |
| Cao, C | 1 |
| Lu, S | 1 |
| Sowa, A | 1 |
| Kivlin, R | 1 |
| Amaral, A | 1 |
| Chu, W | 1 |
| Yang, H | 1 |
| Bergmann-Leitner, ES | 1 |
| Bennett, TA | 1 |
| Hacker, NF | 1 |
| Stromberg, K | 1 |
| Stetler-Stevenson, WG | 1 |
5 other studies available for pd 153035 and Ovarian Neoplasms
| Article | Year |
|---|---|
An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; ErbB Receptors; Female; G | 2005 |
Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Topics: Acetylation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chromones; Dose-Res | 2006 |
Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; CpG Islands; DNA Methylati | 2007 |
Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation | 2008 |
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Topics: Antigens, CD; Autocrine Communication; Carcinoma; Cell Adhesion; Cell Movement; Cell Size; DNA, Anti | 2001 |